Drug Name Indication Company Cost (U.S.) Notes
------------------------------------- --------------------------------------------- ----------------------------------- ------------------------------------ ------------------------------------
Palbociclib (Ibrance) ER+/HER2- breast cancer (2015) Pfizer $13,000-$15,000/mo ($156K-$180K/yr) 30-day ~$14,500 (GoodRx, 2024)
Abraxane + Gemcitabine Pancreatic cancer (2013) Celgene / Generic $15,000-$25,000/6mo Varies by cycle (Drugs.com, 2024)
Pembrolizumab (Keytruda) Colorectal, cervical cancer (2020, 2024) Merck $10,000-$11,000/infusion ($150K/yr) 200 mg dose
Enzalutamide (Xtandi) Prostate cancer (2012) Pfizer / Astellas $12,000-$13,000/mo ($144K-$156K/yr) 30-day ~$12,500 (GoodRx, 2024)
Abemaciclib (Verzenio) HR+/HER2- breast cancer (2017) Eli Lilly $13,000-$15,000/mo ($156K-$180K/yr) Similar to palbociclib
Larotrectinib (Vitrakvi) NTRK fusion cancers (2018) Bayer $32,000-$34,000/mo ($384K-$408K/yr) High cost, rare indication
Dostarlimab (Jemperli) Endometrial, rectal cancer (2021, 2024) GlaxoSmithKline $10,000-$12,000/infusion ($120K/yr) 500 mg dose
Talazoparib (Talzenna) BRCA breast cancer (2018) Pfizer $14,000-$16,000/mo ($168K-$192K/yr) PARP inhibitor
Rucaparib (Rubraca) BRCA ovarian cancer (2016) Clovis Oncology $12,000-$14,000/mo ($144K-$168K/yr) PARP inhibitor
Zenocutuzumab (Bizengri) NRG1 pancreatic/lung cancers (2024) Merus $15,000-$20,000/mo ($180K-$240K/yr) Estimated cost